Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
UNC2399
CAS:<p>UNC2399, a biotinylated version of UNC1999, functions as a selective degrader of EZH2 and exhibits strong in vitro efficacy against EZH2, demonstrated by its IC</p>Fórmula:C67H104N10O17SCor e Forma:SolidPeso molecular:1353.68SAMβA TFA
<p>SAMβA TFA, a selective antagonist of Mfn1-βIIPKC association conjugated to the cell permeable peptide TAT47-57, is a rationally designed inhibitor that improves</p>Fórmula:C50H73N17O16·xC2HF3O2Pureza:98%Cor e Forma:SolidPeso molecular:1168.22 (free acid)Dihydrochlamydocin
CAS:<p>Dihydrochlamydocin, an inhibitor of histone deacetylases (HDAC), exhibits potent cytostatic activity against mastocytoma cells.</p>Fórmula:C28H40N4O6Cor e Forma:SolidPeso molecular:528.65HIF1-IN-3
CAS:<p>HIF1-IN-3 (Benzenepropanamide, N-[(8-hydroxy-7-quinolinyl)(4-methoxyphenyl)methyl]-) is an effective inhibitor of HIF-1 (EC50 = 0.9 μM) and can be used in</p>Fórmula:C26H24N2O3Pureza:99.59%Cor e Forma:SolidPeso molecular:412.48JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Cor e Forma:Odour SolidHSP70/SIRT2-IN-1
<p>HSP70/SIRT2-IN-1 (Compound 2a) serves as a dual inhibitor targeting both SIRT2 and HSP70, exhibiting an IC50 of 17.3±2.0 μM against SIRT2.</p>Pureza:98%Cor e Forma:Odour SolidFoenumoside B
CAS:<p>Foenumoside B, a triterpene saponin extracted from Lysimachia foenum-graecum, stimulates AMPK signaling, suppresses PPARγ-induced adipogenesis, and promotes</p>Fórmula:C60H96O25Pureza:98%Cor e Forma:SolidPeso molecular:1217.39SJ44236
<p>SJ44236 is a BET PROTAC degrader capable of degrading BRD2 (DC50 = 0.127 nM), BRD3, and BRD4. It shows cytotoxicity in MV4-11 and HD-MB03 cells with IC50 values of 0.12 nM and 0.92 nM, respectively. The compound downregulates c-Myc expression and upregulates p53 expression. In mice, SJ44236 demonstrates good oral bioavailability (45%). [Pink: ligand for target protein JQ-1 carboxylic acid; Black: linker; Blue: ligand for E3 ligaseCereblonE3ligaseLigand 54]</p>Fórmula:C40H45ClN8O3SCor e Forma:SolidPeso molecular:753.36AB3067
<p>AB3067 is a PROTAC degrader targeting BET protein, efficiently recruiting two distinct E3 ligases, Cereblon and VHL, with strong affinity (demonstrated by IC50 values of 559 nM for VHL and 190 nM for CRBN in vivo HEK293). It degrades BRD2, BRD3, BRD4, and CRBN with DC50 values of 2.1~2.3, 1.6, 15, and 75 nM, respectively. Additionally, AB3067 inhibits the proliferation of RKO cells, with an EC50 of 111 nM. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase VHL and CRBN)</p>Fórmula:C74H91ClFN11O17S2Cor e Forma:SolidPeso molecular:1525.16ZINC000014708529
<p>ZINC000014708529 is a potent SIRT7 inhibitor exhibiting high affinity for SIRT7 and is utilized in cancer research [1].</p>Cor e Forma:Odour SolidPROTAC BRD4 Degrader-9
CAS:<p>PROTAC BRD4 Degrader-9 degrades BRD4 in PC3 cells; binds VHL and BRD4; DC50: STEAP1-0.86 nM, CLL1-7.6 nM.</p>Fórmula:C59H71F2N9O15S4Cor e Forma:SolidPeso molecular:1312.5ZXH-3-26
CAS:<p>ZXH-3-26 is a PROTAC composed of a Cereblon ligand, an E3 ubiquitin ligase, and a BRD4 ligand that can be used to study cancer.</p>Fórmula:C38H37ClN8O7SPureza:98.90% - 98.90%Cor e Forma:SolidPeso molecular:785.27PRMT5-IN-12
CAS:<p>PRMT5-IN-12 shows remarkable inhibitory activity on PRMT5 .</p>Fórmula:C32H40N4O4Cor e Forma:SolidPeso molecular:544.696PI3Kα/HDAC6-IN-1
<p>PI3Kα/HDAC6-IN-1 (compound 21j) is a dual inhibitor of PI3Kα and HDAC6, exhibiting IC50 values of 2.9 nM and 26 nM, respectively.</p>Fórmula:C27H30F3N7O6S2Pureza:98%Cor e Forma:SolidPeso molecular:669.7HIV-1 protease-IN-10
<p>HIV-1 protease-IN-10 (Compound 2), exhibiting HIV-1 latency reversing activity (IC50: 0.22 μM), selectively binds to the PKCδ C1b domain (IC50: 0.69 μM) and</p>Fórmula:C23H40O5Pureza:98%Cor e Forma:SolidPeso molecular:396.56MNN-02-155
CAS:<p>MNN-02-155 is a bivalent molecular glue that can simultaneously interact with both p300/CBP and BCL6. It effectively induces the activation of BCL6-targeted reporter genes and promotes cell death. This compound is used in the research of diffuse large B-cell lymphoma (DLBCL).</p>Fórmula:C56H68ClF2N15O7Cor e Forma:SolidPeso molecular:1136.69PARP/EZH2-IN-1
CAS:<p>PARP/EZH2-IN-1: Dual PARP (IC50 6.87 nM) & EZH2 (IC50 36.51 nM) inhibitor, potential for BRCA-wild-type triple-negative breast cancer.</p>Fórmula:C43H41FN8O5Cor e Forma:SolidPeso molecular:768.85TAT-cyclo-CLLFVY
CAS:<p>Blocks HIF-1α/β dimerization, not HIF-2α; suppresses VEGF, CAIX in cancer cells; antiangiogenic in HUVECs (IC50 = 1.3 μM).</p>Fórmula:C111H188N42O24S2Pureza:98%Cor e Forma:SolidPeso molecular:2559.1Sirtuin modulator 5
CAS:<p>Sirtuin modulator 5 activates SIRT1 (<50 μM DC50), may extend cell lifespan, and could aid in researching various age/stress-related diseases.</p>Fórmula:C24H23N3O4Cor e Forma:SolidPeso molecular:417.46ZMF-23
<p>ZMF-23, a PAK1/HDAC6 dual inhibitor, suppresses PAK1 and HDAC6-mediated aerobic glycolysis and cellular migration while inducing TNF-α-regulated necroptosis and</p>Fórmula:C22H23Cl2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:476.36IQZ23
CAS:<p>IQZ23 inhibits fat cell formation, activates AMPK, cuts triglycerides (EC50=0.033 μM), may aid obesity/metabolic study.</p>Fórmula:C26H29N5O2Cor e Forma:SolidPeso molecular:443.551KDM2B-IN-2
CAS:<p>KDM2B-IN-2 is a potent histone demethylase (kdm2b) inhibitor.</p>Fórmula:C21H26N4O2S2Pureza:98.96%Cor e Forma:SolidPeso molecular:430.59FKBP12 PROTAC dTAG-7
CAS:<p>dTAG-7 selectively degrades BRD4 and FKBP12F36V by linking BET bromodomains to E3 ligase CRBN; it's a heterobifunctional degrader.</p>Fórmula:C63H79N5O19Pureza:98%Cor e Forma:SolidPeso molecular:1210.32SYY-B085-1
CAS:<p>SYY-B085-1 is a histone acetyltransferase (HAT) inhibitor.</p>Fórmula:C27H23F4N5O4Cor e Forma:SolidPeso molecular:557.506HD-TAC7
<p>HD-TAC7 is a PROTAC HDAC degrader; IC50s: HDAC1 (3.6μM), HDAC2 (4.2μM), HDAC3 (1.1μM); reduces NF-κB p65; researched for asthma, COPD.</p>Fórmula:C33H32FN7O7Cor e Forma:SolidPeso molecular:657.65PARP1-IN-35
<p>PARP1-IN-35 (compound T26) is a selective, orally active PARP1 inhibitor that can cross the blood-brain barrier, with IC50 values of 0.2 nM for PARP1 and 122 nM for PARP2. It exhibits antiproliferative and anticancer activities and holds potential for breast cancer research.</p>Fórmula:C22H21N5OCor e Forma:SolidPeso molecular:371.435XYD198
<p>XYD198 (Compound 14h) is an orally active degrader of CBP/p300. It inhibits the CBP/p300 bromodomain with an IC50 of 213.5 nM and exhibits antitumor activity against acute myeloid leukemia.</p>Fórmula:C54H49F2N11O7Peso molecular:1001.37845JPS016
CAS:<p>JPS016: benzamide VHL E3-ligase PROTAC, degrades HDAC1/2, triggers apoptosis in HCT116 cells.</p>Fórmula:C48H63N7O8SCor e Forma:SolidPeso molecular:898.12GSK3735967
CAS:<p>GSK3735967: DNMT1 inhibitor, IC50 40 nM, dicyanopyridine core, binds hemimethylated CpG, interacts with H4K20me3.</p>Fórmula:C25H31N7OSCor e Forma:SolidPeso molecular:477.62PROTAC BRD4 Degrader-13
CAS:<p>PROTAC BRD4 Degrader-13 targets VHL and BRD4, degrading BRD4 with DC50 of 0.025/6.0 nM in PC3 cells when linked to STEAP1/CLL1 antibodies.</p>Fórmula:C68H85F2N11O17P2S2Cor e Forma:SolidPeso molecular:1492.55TNKS-2-IN-2
CAS:<p>TNKS-2-IN-2 is a TNKS2 selective inhibitor (IC50: 22 nM) with potential anti-tumour activity for the study of colon cancer lung cancer and breast cancer.</p>Fórmula:C26H23N3O6Pureza:99.45%Cor e Forma:SoildPeso molecular:473.48PROTAC BRD9 Degrader-1
CAS:<p>PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader with IC50 of 13.5 nM.</p>Fórmula:C42H45N7O12S2Pureza:98%Cor e Forma:SolidPeso molecular:903.98BRM/BRG1 ligand 1
CAS:<p>BRM/BRG1 Ligand 1 is a BRM/BRG1 ligand utilized for the synthesis of PROTAC BRM/BRG1 degrader-1.</p>Fórmula:C10H8BrN3OCor e Forma:SolidPeso molecular:266.09JMJD6 inhibitor WL12
CAS:<p>WL12 (ZINC6733033): First-in-class JMJD6 inhibitor; halts JMJD6-dependent cervical/liver cancer cell growth.</p>Fórmula:C16H11N3O2Pureza:98.57%Cor e Forma:SolidPeso molecular:277.28PROTAC BRM/BRG1 degrader-1
CAS:<p>PROTAC BRM/BRG1 degrader-1 is a chemical compound that acts as a degrader of PROTAC BRM/BRG1, exhibiting a DC50 range of 10-100 nM (BRM) and > 1 μM (BRG1). This compound is utilized in cancer research.</p>Fórmula:C54H63N9O9SCor e Forma:SolidPeso molecular:1014.2Ep300/CREBBP-IN-3
CAS:<p>Ep300/CREBBP-IN-3 inhibits Ep300 & CREBBP (IC50: 0.056 & 0.095 μM respectively); potential for cancer research.</p>Fórmula:C26H25F4N5O3Cor e Forma:SolidPeso molecular:531.50MS049 2HCl (1502816-23-0(free base))
<p>MS049 inhibits PRMT4 (IC50=34nM) & PRMT6 (IC50=43nM), less so for PRMT1, PRMT3, PRMT8, not others.</p>Fórmula:C15H26Cl2N2OPureza:99.9%Cor e Forma:SolidPeso molecular:321.28PKC β pseudosubstrate
CAS:<p>Selective cell-permeable peptide inhibitor of protein kinase C (IC50 ~ 0.5 μM).</p>Fórmula:C177H294N62O38S3Pureza:98%Cor e Forma:SolidPeso molecular:3994.84PROTAC BRM/BRG1 degrader-2
CAS:<p>PROTAC BRM/BRG1 degrader-2 (Example.004) is a potent PROTAC BRM/BRG1 degrading agent exhibiting a DC50 of less than 10 nM and an IC50 of 15 nM in A549 cells.</p>Fórmula:C50H60N12O5SCor e Forma:SolidPeso molecular:941.15HDAC1/2-IN-3
CAS:<p>HDAC1/2-IN-3 is an inhibitor of both HDAC1 and HDAC2, demonstrating IC50 values of 0-5 nM and 5-10 nM, respectively.</p>Fórmula:C24H25N5OSCor e Forma:SolidPeso molecular:431.56Okicenone
CAS:<p>Okicenone is an antibiotic, interferring with HuR RNA binding, HuR trafficking, T-cell activation and cytokine expression.</p>Fórmula:C15H14O4Cor e Forma:SolidPeso molecular:258.27BAY-184
CAS:<p>BAY-184,KAT6A/B inhibitor (IC50=71/83 nM). Suppresses ERα activity. Impedes breast cancer proliferation.</p>Fórmula:C23H20N2O4SPureza:98.87%Cor e Forma:SolidPeso molecular:420.48MRTX9768 hydrochloride
<p>MRTX9768 hydrochloride is a potent, orally active PRMT5 inhibitor.</p>Cor e Forma:SolidJQ1-TCO
CAS:<p>JQ1-TCO, a BET inhibitor derivative, enables click chemistry for molecular probing in vivo and in vitro.</p>Fórmula:C31H37ClN6O3SCor e Forma:SolidPeso molecular:609.18PROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Fórmula:C55H69N13O7SPureza:98%Cor e Forma:SolidPeso molecular:1056.28Cy3 MicroRNA Antagomir Negative Control
<p>Cy3 MicroRNA Antagomir Negative Control is a Cy3-labeled MicroRNA Antagomir designed as a negative control. The sequence of this control is based on cel-mir-239b, a sequence commonly used as a control due to its minimal sequence homology with human, mouse, and rat miRNA.</p>Cor e Forma:Odour SolidEZH2-IN-5
CAS:<p>EZH2-IN-5, potent EZH2 inhibitor; IC50: 1.52 nM (wild-type), 4.07 nM (Tyr641 mutant).</p>Fórmula:C26H37BrN4O2Cor e Forma:SolidPeso molecular:517.512PROTAC HDAC6 degrader 3
<p>PROTACHDAC6 degrader 3 (Compound 4) is a selective inhibitor and degrader of HDAC6, with an IC50 of 686 nM and a DC50 of 171 nM. It enhances the acetylation of α-tubulin. [Pink: ligand for target protein; Blue: ligand for E3ligaseVHL.]</p>Fórmula:C46H56F2N10O9SCor e Forma:SolidPeso molecular:963.06PROTAC BET degrader-3
<p>PROTAC BET Degrader-3 is a potent degrader OF BET based on PROTAC.</p>Fórmula:C53H64N12O9SPureza:98%Cor e Forma:SolidPeso molecular:1045.22PF-04577806
CAS:<p>PF-04577806: potent & selective PKC inhibitor, ATP competitive, blocks PKCα/βI/βII/γ/θ (IC50: 2.4-45.9 nM), may reverse diabetic retinal leakage.</p>Fórmula:C26H37N7O3Cor e Forma:SolidPeso molecular:495.628Dihydrochlamydocin analog-1
CAS:<p>Dihydrochlamydocinanalog-1 (compound 2) is a Chlamydocin analog that inhibits the deacetylation of histone H4 peptides, with an IC50 of 30 nM.</p>Fórmula:C28H40N4O6Cor e Forma:SolidPeso molecular:528.64Lyngbyatoxin A
CAS:<p>Lyngbyatoxin A is an indole alkaloid from blue-green alga Lyngbya majuscula Gomont; responsible for dermatitis known as &quot;swimmers' itch&quot; in Hawaii.</p>Fórmula:C27H39N3O2Cor e Forma:SolidPeso molecular:437.62DNA Damage & Repair Compound Library
<p>A unique collection of xnum DNA Damage &amp; Repair related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Cor e Forma:Odour SolidThalidomide-NH-CBP/p300 ligand 2
CAS:<p>Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based compound designed to degrade CBP and p300, acting as a functional antagonist (WO2020173440).</p>Fórmula:C48H57F2N11O6Cor e Forma:SolidPeso molecular:922.052Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Cor e Forma:Odour SolidmTOR/HDAC-IN-1
CAS:<p>mTOR/HDAC-IN-1, a dual inhibitor for mTOR & HDAC1 with IC50s 0.49 & 0.91 nM, potential anti-cancer agent.</p>Fórmula:C23H23N11O3Cor e Forma:SolidPeso molecular:501.5RMM23
<p>RMM23 is an inhibitor that targets PfBDP1, exhibiting a Kd of 1.24 μM. In vitro, it shows EC50 values of 18 μM against the 3D7 wild-type strain, 14 μM against the NF54 wild-type strain, and 20 μM against the multidrug-resistant K1 strain during the blood stage.</p>Cor e Forma:Odour SolidPBRM1-BD2-IN-2
CAS:<p>PBRM1-BD2-IN-2 selectively inhibits PBRM1 with Kd 9.3μM & IC50 1.0μM, useful in cancer research.</p>Fórmula:C14H9Cl2FN2OPureza:99.88%Cor e Forma:SoildPeso molecular:311.14Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77MS33
CAS:<p>MS33 degrades WDR5 protein, Kd 870 nM (VCB), 120 nM (WDR5); uses VHL ligase, aids acute myeloid leukemia study.</p>Fórmula:C64H84F3N11O7SCor e Forma:SolidPeso molecular:1208.5JB300
CAS:<p>JB300 is a PROTAC-based compound that serves as a highly selective degrader of Aurora A, with a DC50 of 30 nM. It is utilized in cancer research. JB300 comprises the PROTAC target protein ligand MK-5108 [pink part], E3 ligase ligand Thalidomide-O-COOH [blue part], and PROTAC Linker Boc-NH-PEG2-C2-NH2 [black part]. The conjugate of the E3 ubiquitin ligase ligand and linker is Thalidomide-O-COOH-NH2-C2-PEG2-NH-Boc.</p>Fórmula:C43H45ClFN7O10SCor e Forma:SolidPeso molecular:906.375Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Fórmula:C17H20N8O2SPureza:99.94%Cor e Forma:SoildPeso molecular:400.467-Hydroxyneolamellarin A
CAS:<p>7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.</p>Fórmula:C24H19NO5Cor e Forma:SolidPeso molecular:401.41XF067-68
CAS:<p>XF067-68 is a PROTAC for targeted degradation of WD40 repeat domain protein 5 ( WDR5 )[1] .</p>Fórmula:C52H59F4N9O7SCor e Forma:SolidPeso molecular:1030.14(S)-GNE-987
<p>(S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC).</p>Fórmula:C56H67F2N9O8S2Pureza:98%Cor e Forma:SolidPeso molecular:1096.31PRO-HD3
<p>PRO-HD3 is a cell-specific, PROTAC-based degrader targeting HDAC6 [1].</p>Pureza:98%Cor e Forma:Odour SolidKB02-JQ1
CAS:<p>KB02-JQ1: potent BRD4-degrading PROTAC, stable, specific; doesn't affect BRD2/3, modifies DCAF16 for action.</p>Fórmula:C38H43Cl2N7O6SPureza:98%Cor e Forma:SoildPeso molecular:796.76MS9024
<p>MS9024 is a degrader of DNA methyltransferase 1 (DNMT1), facilitating its degradation in HCT116 cells via the ubiquitin-proteasome pathway, with a DC50 of 35 nM (DC50 values are 254 nM in MDA-MB-468 and 101 nM in H1299). Additionally, MS9024 inhibits DNMT1 with an IC50 of 0.43 μM.</p>Cor e Forma:Odour SolidNSC 370284
CAS:<p>NSC 370284 inhibits STAT3/5, reducing AML cell viability with TET1 overexpression in vitro/in vivo.</p>Fórmula:C21H25NO6Pureza:99.74%Cor e Forma:SolidPeso molecular:387.43R8-T198wt
CAS:<p>Cell-permeable peptide blocking Pim-1 kinase, halts DU145 cell growth, causes G1 arrest and apoptosis, inert to RPWE-1 cells at 10-20 μM.</p>Fórmula:C111H211N59O26SPureza:98%Cor e Forma:SolidPeso molecular:2820.33KDM1A-IN-29
CAS:<p>KDM1A-IN-29 is a histone demethylase inhibitor.</p>Fórmula:C16H16ClN3O4SCor e Forma:SoildPeso molecular:381.83TDI-012804
<p>TDI-012804 is a TNKS2 inhibitor that selectively inhibits endogenous TNKS2 protein within cells. It enhances the expression of AXIN1 protein in Tnks1 heterozygous (Tnks1HET) and knockout (Tnks1KO) cells. TDI-012804 suppresses the proliferation of ApcQ1405X/Tnks1KO organoids with an EC50 of 59.1 nM and exhibits selective toxicity towards Tnks1KO AKP-G12D and AKP-G13D organoids.</p>Cor e Forma:Odour SolidAxl-IN-16
<p>Axl-IN-16, a dual Axl/HIF inhibitor, promotes Flammulina velutipes fruiting body formation and suppresses hypoxia-inducible factor activity along with receptor</p>Fórmula:C14H19ClO8Pureza:98%Cor e Forma:SolidPeso molecular:350.75Bryostatin 3
CAS:<p>Bryostatin 3 is a protein kinase C activator.</p>Fórmula:C46H64O17Pureza:98%Cor e Forma:SolidPeso molecular:888.99SNIPER(BRD)-1
CAS:<p>SNIPER(BRD)-1 has LCL-161, (+)-JQ1 linked; degrades BRD4, cIAP1/2, XIAP; IC50s: 6.8, 17, 49nM.</p>Fórmula:C53H66ClN9O8S2Pureza:98%Cor e Forma:SolidPeso molecular:1056.73ZIP
CAS:<p>Novel inhibitor for PKMζ, halts synaptic potentiation and reverses LTP with IC50 of 1-2.5 μM, erasing spatial memory.</p>Fórmula:C90H154N30O17Pureza:98%Cor e Forma:SolidPeso molecular:1928.4Namoline
CAS:<p>Namoline, a γ-pyrone, inhibits LSD1 with a 51 μM IC50, blocking cell growth and showing potential in prostate cancer studies.</p>Fórmula:C10H3ClF3NO4Cor e Forma:SolidPeso molecular:293.58Wnt/β-catenin-IN-5
<p>Wnt/β-catenin-IN-5 (Compound 4) functions as an inhibitor of the Wnt/β-catenin signaling pathway. This compound effectively eradicates colorectal cancer stem cells and inhibits tumor growth by suppressing the Wnt signaling pathway. Additionally, Wnt/β-catenin-IN-5 promotes the degradation of KDM3A and KDM3B.</p>Fórmula:C33H37N5O10Cor e Forma:SolidPeso molecular:663.67EZH2-IN-15
CAS:<p>A compound inhibits EZH2, overexpressed in cancers, affecting Treg activity and innate immunity.</p>Fórmula:C32H44N4O4Pureza:99.88%Cor e Forma:SolidPeso molecular:548.72HIF-1 α (556-574)
CAS:<p>HIF-1 alpha (556-574) is a 19-mer fragment vital for gene expression in low oxygen; it binds VHL with critical proline 564 for stability.</p>Fórmula:C101H150D2N20O34S2Pureza:98%Cor e Forma:SolidPeso molecular:2254.6ZL0590
CAS:<p>ZL0590 is an effective and selective inhibitor of BD1-BRD4 (IC50 = 90 nM) with anti-inflammatory activities.</p>Fórmula:C23H27F3N4O4SPureza:99.77%Cor e Forma:SoildPeso molecular:512.55PROTAC BRD9-binding moiety 1
CAS:<p>PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.</p>Fórmula:C23H25N3O7S2Pureza:98%Cor e Forma:SolidPeso molecular:519.59CPI-268456
CAS:<p>CPI-268456 is a compound which has bioactive.</p>Fórmula:C20H15Cl2N3O2Cor e Forma:SolidPeso molecular:400.26GSK040
CAS:<p>GSK040: Potent BET BD2 inhibitor, pIC50 8.3, 5000x selectivity over BD1, for oncology & immunology research.</p>Fórmula:C29H34N4O4Cor e Forma:SolidPeso molecular:502.6SMD-3040 TFA
<p>SMD-3040 TFA is a selective SMARCA2 degrader comprising SMARCA2/4 ligands, a linker, and VHL ligands, utilized in PROTAC drug synthesis.</p>Pureza:98%Cor e Forma:Odour SolidPROTAC BRD4 Degrader-19
CAS:<p>PROTAC BRD4 Degrader-19 (compound 176) is a proteolysis-targeting chimera (PROTAC) designed to specifically degrade the BRD4 protein, offering potential utility</p>Fórmula:C44H38N8O5S2Cor e Forma:SolidPeso molecular:822.95DS-103
<p>DS-103 is an HDAC inhibitor that targets HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 with IC50 values of 0.029, 0.123, 0.022, 0.367, and 9.26 μM, respectively. It also inhibits the malignant malaria parasite [Plasmodium falciparum 3D7] with an IC50 of 5.08 μM. In A2780 and Cal27 cells, DS-103 exhibits cytotoxicity with IC50 values of 1.48 μM and 1.47 μM, respectively, and reverses cisplatin resistance in these cells with IC50 values of 4.62 μM and 2.23 μM. DS-103 acts synergistically with cisplatin, enhancing apoptosis induced by cisplatin.</p>Fórmula:C28H33N5O3Cor e Forma:SolidPeso molecular:487.59GSK8573
CAS:<p>GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).</p>Fórmula:C20H21NO3Pureza:99.81%Cor e Forma:SolidPeso molecular:323.39BRD7-IN-1 free base
CAS:<p>BRD7-IN-1, a BI7273 derivative, transforms into PROTAC VZ185 (targets BRD7/9 with 4.5/1.8 nM DC50s) via a VHL linker.</p>Fórmula:C22H26N4O3Pureza:98%Cor e Forma:SolidPeso molecular:394.47XF056-132
CAS:<p>XF056-132 is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader [1] .</p>Fórmula:C51H57F4N9O7SCor e Forma:SolidPeso molecular:1016.11PROTAC BRD4 Degrader-7
CAS:<p>PROTAC BRD4 Degrader-7, from patent WO2020055976A1, has IC50 of 15.5 nM (BD1) & 12.3 nM (BD2).</p>Fórmula:C26H29N5O2SCor e Forma:SolidPeso molecular:475.61MNK/PIM-IN-1
CAS:<p>MNK/PIM-IN-1 is a novel dual inhibitor targeting both MNK and PIM pathways, characterized by its favorable pharmacokinetic profile.</p>Fórmula:C27H27FN6O2Cor e Forma:SolidPeso molecular:486.551BRD4 Inhibitor-16
<p>BRD4 Inhibitor-16 (Compound 4) is a potent suppressor of BRD4 linked to cancer, aiding in research of BRD4-related treatments.</p>Fórmula:C42H43N7O8SCor e Forma:SolidPeso molecular:805.9PROTAC BRM/BRG1 degrader-4
<p>PROTAC BRM/BRG1 degrader-4 (example 047) is a potent degrader targeting both BRM and BRG1, demonstrating DC50 values of 0.21 nM and 3.4 nM respectively in SW1573 cells.</p>Fórmula:C44H52N10O6SCor e Forma:SolidPeso molecular:849.01M-1211
CAS:<p>M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression.</p>Fórmula:C42H57FN6O6SCor e Forma:SolidPeso molecular:793.01HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SCor e Forma:SolidPeso molecular:1236.36DC-S239
CAS:<p>Ethyl 2-amino-4-methyl-5-thiophene carboxylate is a SETD7 inhibitor (IC50=4.59μM) with anticancer properties.</p>Fórmula:C15H15N3O5SPureza:99.37%Cor e Forma:SolidPeso molecular:349.36SAH-EZH2
CAS:<p>EZH2/EPP inhibitor, Kd 320 nM. Reduces EZH2, H3K27me3; halts MLL-AF9 leukemia growth; drives monocyte-macrophage differentiation.</p>Fórmula:C155H256N48O40Pureza:98%Cor e Forma:SolidPeso molecular:3432.05JAK2-IN-6
CAS:<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Fórmula:C14H10ClN3OS2Pureza:99.64%Cor e Forma:SolidPeso molecular:335.83CBP/p300-IN-8
CAS:<p>CBP/p300-IN-8 strongly inhibits CBP/P300 bromodomains; CBP IC50=0.01-0.1μM, BRD4 IC50=1-1000μM.</p>Fórmula:C27H31N3O4Cor e Forma:SolidPeso molecular:461.562JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour Solid3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol
CAS:<p>3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol is a compound that functions as a SIRT1 activator, effectively enhancing SIRT1 activity.</p>Fórmula:C30H52O4Cor e Forma:SolidPeso molecular:476.7425H-BENZO[E]PYRIDO[3,2-B][1,4]DIAZEPIN-6(11H)-ONE
CAS:Fórmula:C12H9N3OCor e Forma:SolidPeso molecular:211.21Dot1L-IN-9
<p>Dot1L-IN-9 (Compound 12) is a DOT1L inhibitor with an IC50 of 125 nM. It effectively reduces H3K79 dimethylation and is utilized in leukemia research.</p>Cor e Forma:Odour SolidPROTAC BET Degrader-10
CAS:<p>PROTAC BET Degrader-10 targets and degrades BRD4 with a DC50 of 49 nM, using Cereblon ligands.</p>Fórmula:C39H39ClN8O6SCor e Forma:SolidPeso molecular:783.3GSK-1070916
CAS:<p>GSK-1070916 (GSK-1070916A) is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM.</p>Fórmula:C30H33N7OPureza:99.73%Cor e Forma:SolidPeso molecular:507.63DAO-dBET1
<p>DAO-dBET1, a dual-action PROTAC incorporating the PROTAC degrader dBET1, effectively serves as a potent BRD4 degrader and exhibits a DC50 value of 277 nM in the presence of CoCl2. Additionally, DAO-dBET1 inhibits hypoxia and Cath-L activation with an IC50 value of 281 nM.</p>Cor e Forma:Odour SolidHDAC6-IN-53
<p>HDAC6-IN-53 (Compound W28) is an inhibitor targeting histone deacetylase 6 (HDAC6) with an IC50 of 19.65 nM. It reduces the idiopathic pulmonary fibrosis (IPF) phenotype by inhibiting TGF-β1-induced collagen expression and demonstrates therapeutic efficacy in a bleomycin-induced mouse model of pulmonary fibrosis. HDAC6-IN-53 is applicable for research in idiopathic pulmonary fibrosis and related pulmonary fibrotic diseases.</p>Cor e Forma:Odour SolidSAMS
CAS:<p>SAMS peptide is a specific substrate for the AMP-activated protein kinase (AMPK).</p>Fórmula:C74H131N29O18S2Pureza:98%Cor e Forma:SolidPeso molecular:1779.15Sphingosine (d14:1)
CAS:<p>Sphingosine (d14:1) boosts N. rileyi fungus growth, inhibits PKC, and reduces CHO cell proliferation; found in various sea creatures.</p>Fórmula:C14H29NO2Cor e Forma:SolidPeso molecular:243.39Go6976
CAS:<p>Go6976 is a PKC inhibitor, widely used in research to probe PKC functions in health and disease.</p>Fórmula:C24H18N4OPureza:95.89%Cor e Forma:Off-White To Yellow SolidPeso molecular:378.43N-Desmethyltamoxifen
CAS:<p>N-Desmethyltamoxifen, tamoxifen's main human metabolite, regulates AML cell ceramide metabolism and is a more potent PKC inhibitor than tamoxifen.</p>Fórmula:C25H27NOPureza:98%Cor e Forma:SolidPeso molecular:357.49Myelin Basic Protein
CAS:<p>Myelin basic protein (MBP) is a protein believed to be important in the process of myelination of nerves in the nervous system.</p>Fórmula:C60H103N21O17Pureza:98%Cor e Forma:SolidPeso molecular:1390.59G9a-IN-3
<p>G9a-IN-3 (compound 16g) is a potent G9a inhibitor with an IC50 of 0.002 μM. It is applicable for research in sickle cell disease.</p>Fórmula:C26H29N5O3Cor e Forma:SolidPeso molecular:459.22704[Ala107]MBP(104-118)
CAS:<p>Synthetic peptide analog of bovine myelin basic protein (MBP). Non-competitive inhibitor of PKC (IC50 = 46 - 145 mM).</p>Fórmula:C67H104N20O19Pureza:98%Cor e Forma:SolidPeso molecular:1493.68CM112
<p>CM112 is a selective degrader of protein arginine methyltransferase 1 (PRMT1), which connects a hydrophobic adamantane tag to MS023 via a 5-PEG linker. It induces the degradation of PRMT1 in various solid tumor cell lines. CM112 also targets the non-enzymatic functions of PRMT1 by reducing the stability of the orphan receptor TR3. This compound shows potential for cancer research.</p>Fórmula:C39H61N5O7Cor e Forma:SolidPeso molecular:711.4571Echinomycin
CAS:<p>Echinomycin (Quinomycin A) is a quinoxaline antibiotic and a DNA-intercalating peptide that inhibits hypoxia-inducible factor-1 (HIF-1) DNA binding activity.</p>Fórmula:C51H64N12O12S2Pureza:95%Cor e Forma:SolidPeso molecular:1101.26PROTAC BRD4-DCAF1 degrader-1
CAS:<p>PROTACBRD4-DCAF1 degrader-1 (I-907) is a PROTAC degrader targeting BRD4-DCAF1, exhibiting a DC50 range of 10~100 nM.</p>Fórmula:C60H64Cl2F2N8O9SCor e Forma:SolidPeso molecular:1182.17(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine
CAS:<p>(S,R,S)-AHPC-C2-amide targets Smad3 degradation and boosts HIF-α; it has anti-fibrotic and renal protective roles.</p>Fórmula:C41H46N6O6SCor e Forma:SolidPeso molecular:750.91Ep300/CREBBP-IN-2
CAS:<p>Ep300/CREBBP-IN-2: Potent, oral Ep300 & CREBBP inhibitor; IC50s: 0.052μM & 0.148μM; cancer research.</p>Fórmula:C26H27F3N4O4Cor e Forma:SolidPeso molecular:516.51UNC 0631
CAS:<p>UNC 0631 is a effectvie histone methyltransferase G9a inhibitor (IC50=4 nM).</p>Fórmula:C37H61N7O2Pureza:98.76%Cor e Forma:SolidPeso molecular:635.93PROTAC BRD4 Degrader-20
CAS:<p>PROTAC BRD4 Degrader-20 (compound 195) is a bifunctional degrader of BRD4 [1].</p>Fórmula:C55H58ClN9O7S2Cor e Forma:SolidPeso molecular:1056.69WDR5-MYC-IN-1
<p>WDR5-MYC-IN-1 (compound 4o) is an effective inhibitor of the WDR5-MYC interaction, demonstrating a Ki value of 1.0 µM and exhibiting antiproliferative activity.</p>Cor e Forma:Odour SolidMRK-990
<p>MRK-990 is an inhibitor of PRMT that targets both PRMT5 and PRMT9, with IC50 values of 30 nM and 10 nM, respectively.</p>Cor e Forma:Odour SolidGSK097
CAS:<p>GSK097: Potent, selective BD2 inhibitor in BET proteins; 2000x more selective for BD2 than BD1; soluble >1 mg/mL in FaSSIF.</p>Fórmula:C19H21N3O3Cor e Forma:SolidPeso molecular:339.395coumarin-SAHA
CAS:<p>SAHA inhibits class I/II HDAC; c-SAHA, a fluorescent derivative, excites at 325 nm and emits at 400 nm.</p>Fórmula:C18H22N2O5Cor e Forma:SolidPeso molecular:346.383JWZ-7-7-Neg1
CAS:<p>JWZ-7-7-Neg1, a neighboring transcription chemical inducer (TCIP), serves as a negative control. It exhibits reduced binding capabilities to BRD4 or BCL6 compared to JWZ-7-7, resulting in lower cytotoxicity towards DLBCL cells.</p>Fórmula:C50H58Cl2N12O6SCor e Forma:SolidPeso molecular:1026.04AZD-9574
CAS:<p>AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs.</p>Fórmula:C21H22F2N6O2Pureza:98.46% - 99.39%Cor e Forma:SolidPeso molecular:428.44GSK973
CAS:<p>GSK973 is a selective oral BET inhibitor, 1600x more for BRD4 BD2 (pIC50 7.8, pKd 8.7) than BD1, effective against other BD2s.</p>Fórmula:C23H23FN2O4Cor e Forma:SolidPeso molecular:410.445LLY-284
CAS:<p>LLY-284, a less active PRMT5 inhibitor diastereomer of LLY-283, serves as its negative control.</p>Fórmula:C17H18N4O4Pureza:98%Cor e Forma:SolidPeso molecular:342.35Protein Kinase C (19-31)
CAS:<p>Protein Kinase C (19-31), a PKC inhibitor derived from PKCa, has a serine at position 25 and tests PKC activity.</p>Fórmula:C67H118N26O16Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:1543.82AUR1545
CAS:<p>AUR1545 is a selective KAT2A/KAT2B degradator exhibiting inhibitory activity against cancer models including AML, SCLC, and NEPC, and suppressing tumour growth in the NCI-H1048 xenograft model.</p>Fórmula:C41H50BrN9O5Pureza:98.84%Cor e Forma:SolidPeso molecular:828.8HDAC-IN-89
<p>HDAC-IN-89 is an inhibitor of HDAC1 (IC50: 0.95 nM), HDAC2 (IC50: 0.86 nM), HDAC3 (IC50: 1.06 nM), and HDAC8 (IC50: 4.24 nM). It can disrupt the cell cycle and induce apoptosis. Additionally, HDAC-IN-89 exhibits antitumor activity.</p>Cor e Forma:Odour SolidJAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Fórmula:C20H12ClN3OCor e Forma:SolidPeso molecular:345.79Fluorescein-NAD+
<p>Fluorescein NAD+ is a non-radioactive PARP assay substrate, enabling direct enzyme measurement by fluorescence. Comes as 81μg in 250μl water.</p>Cor e Forma:SolidSJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SCor e Forma:SolidPeso molecular:818.95dBRD9
CAS:<p>dBRD9 is a PROTAC.</p>Fórmula:C40H45N7O10Pureza:99.81%Cor e Forma:SolidPeso molecular:783.83PRMT5-IN-11
CAS:<p>PRMT5-IN-11 demonstrates potent structure-dependent inhibition against the protein methyltransferase PRMT5:MEP50 complex at submicromolar concentrations.</p>Fórmula:C13H17N5O4Cor e Forma:SolidPeso molecular:307.31PROTAC SMARCA2/4-degrader-28
CAS:<p>PROTAC SMARCA2/4-degrader-28 (PROTAC 1) functions as a partial degrader of SMARCA2 and SMARCA4 through the PROTAC-based mechanism.</p>Fórmula:C54H68ClN9O11S2Cor e Forma:SolidPeso molecular:1118.75Malantide
CAS:<p>Malantide, a synthetic dodecapeptide, boosts and measures PKA activity by undergoing PKA-induced phosphorylation.</p>Fórmula:C72H124N22O21Pureza:98%Cor e Forma:SolidPeso molecular:1633.89iRucaparib-AP6
CAS:<p>iRucaparib-AP6: a specific, non-trapping PARP1 degrader; inhibits the enzyme's activity and scaffolding.</p>Fórmula:C46H55FN6O11Pureza:98%Cor e Forma:SolidPeso molecular:886.96PROTAC HDAC6 degrader 4
<p>PROTAC HDAC6 degrader4 (Compound 17c) is a PROTAC that targets and degrades HDAC6, with a DC50 of 14 nM. It exhibits inhibitory activity against HDAC1, HDAC2, HDAC3, and HDAC6, with IC50 values of 2.2, 2.37, 0.61, and 0.295 μM, respectively. [Pink: ligand for target protein HDAC6 ligand-3; Black: linker; Blue: ligand for cereblon E3 ligase]</p>Fórmula:C39H42FN9O7Cor e Forma:SolidPeso molecular:767.81EZH2-IN-4
CAS:<p>EZH2-IN-4, an oral EZH2 inhibitor, targets WT and mutant forms with IC50s of 0.923 nM and 2.65 nM, showing strong anti-cancer effects.</p>Fórmula:C29H41N3O3SCor e Forma:SolidPeso molecular:511.73PRMT5-IN-15
CAS:<p>PRMT5-IN-15 is a PRMT5 inhibitor with an IC 50 value of 0.84 nM.</p>Fórmula:C24H23F3N6O2Cor e Forma:SolidPeso molecular:484.483DNMT1/HDAC-IN-1
<p>DNMT1/HDAC-IN-1 (compound (R)-23a), a potent dual inhibitor targeting both DNMT1 and HDAC, exhibits impressive inhibitory effects specifically on HDAC1 (HDAC1:IC50=0.05 μM), a major HDAC isoform that interacts with DNMT1 across multiple protein complexes involved in the transcriptional silencing of TSGs. This compound has been shown to remodel the tumor immune microenvironment and induce tumor regression, effectively reversing cancer-specific epigenetic abnormalities.</p>Cor e Forma:Odour SolidCARM1/IKZF3 ligand 1
<p>CARM1/IKZF3 ligand 1 functions as an inhibitor of CARM1 and serves as a target protein ligand for the synthesis of PROTAC CARM1/IKZF3 degrader-1.</p>Fórmula:C27H35ClN6O3Cor e Forma:SolidPeso molecular:527.06HDAC11-IN-1
<p>HDAC11-IN-1 (Compound 14-NC6OH) is a macrocyclic inhibitor that selectively targets HDAC11 with a Ki of 40 nM. It demonstrates effective cell permeability and suppresses the expression of YAP1 and SOX2.</p>Fórmula:C43H63F3N6O6S2Cor e Forma:SolidPeso molecular:881.12ZSNI-21
<p>ZSNI-21 is a dual inhibitor targeting ADAM17 and HDAC2. It effectively suppresses the proliferation of Bel-7402 cells and exhibits significant anti-metastatic properties against HCC-LM3 cells, making it a promising candidate for hepatocellular carcinoma (HCC) research.</p>Fórmula:C26H25N3O5Cor e Forma:SolidPeso molecular:459.49UNC10013
<p>UNC10013 is an allosteric modulator of SETDB1, exhibiting negative allosteric regulation through covalent bond formation with Cys385 on the 3TD domain. It has a kinact/KI value of 1.0 × 10^6 M^-1*s^-1. UNC10013 effectively disrupts SETDB1-mediated Akt methylation, holding potential for application in cancer and neurodegenerative disease research.</p>Cor e Forma:Odour SolidPRMT5 ligand 1
CAS:<p>PRMT5ligand 1 is a ligand of PRMT5, used as a target protein ligand in the synthesis of the PROTAC degrader MS4322.</p>Fórmula:C20H26N6O2Cor e Forma:SolidPeso molecular:382.459Biotinylated-JQ1
CAS:<p>Biotin-JQ1 is a bromodomain BRD4 binder; inhibits MM1.S cell growth with EC50 of 0.4μM.</p>Fórmula:C39H53ClN8O6S2Cor e Forma:SolidPeso molecular:829.47(R)-SKBG-1
CAS:<p>(R)-SKBG-1 is an inhibitor of the RNA-binding protein NONO, effectively downregulating androgen receptor expression by targeting both AR-FL mRNA and AR-V7 mRNA</p>Fórmula:C22H26ClN3O6SPureza:97.25%Cor e Forma:SolidPeso molecular:495.98ML234
<p>ML234 is a dual inhibitor targeting EZH2/LSD1, with IC50 values of 0.09 and 0.12 μM, respectively. It demonstrates strong antiproliferative effects on prostate cancer cell lines LNCAP, PC3, and 22RV1. Additionally, ML234 inhibits tumor growth in a 22RV1 xenograft mouse model, showing potential as a research agent in prostate cancer therapeutics.</p>Cor e Forma:Odour SolidJAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SCor e Forma:SolidPeso molecular:548.67QA-68
<p>QA-68 is a potent BRD9 degrader, inhibits cell growth, and has anti-leukemic properties.</p>Fórmula:C61H72N10O10S2Cor e Forma:SolidPeso molecular:1169.42MACTIDE-V
<p>MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. This compound delivers Verteporfin to CD206+ tumor-associated macrophages (TAM), thereby inhibiting the YAP/TAZ signaling pathway. It facilitates YAP exclusion from the nucleus, induces TAM polarization toward an anti-tumor phenotype, enhances phagocytosis and antigen presentation, and promotes T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models.</p>Fórmula:C109H156N22O27S2Cor e Forma:SolidPeso molecular:2269.09517SGC3027
<p>SGC3027 is an inhibitor of histone methyltransferase,also is a first potent, selective and cell active chemical probe for PRMT7.</p>Fórmula:C41H47ClN6O6SPureza:98%Cor e Forma:SolidPeso molecular:787.37HDAC6 ligand-3
<p>HDAC6ligand-3 serves as a ligand for HDAC6 and can be utilized as a target protein ligand in the synthesis of [PROTAC] HDAC6 degrader4.</p>Fórmula:C20H21N3O3Cor e Forma:SolidPeso molecular:351.399Malantide TFA
<p>Malantide TFA: synthetic dodecapeptide, PKA-specific with Km 15 μM, >90% PKI blockage, also PKC substrate, Km 16 μM.</p>Fórmula:C74H125F3N22O23Cor e Forma:SolidPeso molecular:1747.91Delcasertib acetate
<p>Delcasertib acetate is a selective δ protein kinase C (δPKC) inhibitor for the study of acute myocardial infarction and pain.</p>Fórmula:C122H203N45O36S2Pureza:98.92%Cor e Forma:SolidPeso molecular:2940.33GNE-064
CAS:<p>GNE-064: Oral SMARCA4/2, PBRM1 inhibitor; IC50 (SMARCA4)=0.035µM, EC50 (SMARCA2)=0.1µM; High solubility; Research probe.</p>Fórmula:C17H21N5O2Pureza:99.91%Cor e Forma:SoildPeso molecular:327.38Antidiabetic agent 7
<p>Antidiabetic agent 7 (Compound 5m) functions as a potent hyperglycemia inhibitor. It effectively stimulates GLUT4 translocation in skeletal muscle cells by activating the AMPK-dependent pathway. Additionally, this compound is capable of reducing blood glucose levels and exhibits favorable pharmacokinetic properties. Antidiabetic agent 7 is suitable for research related to antihyperglycemic treatments.</p>Fórmula:C27H21Cl2N5O3Cor e Forma:SolidPeso molecular:534.39NCT-TFP
CAS:<p>NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors[1].</p>Fórmula:C41H34F4N2O5Cor e Forma:SolidPeso molecular:710.71MS479
<p>MS479 is a BRD4 PROTAC degrader that binds with high affinity to BRD4-BD2 and GLP (BRD4-BD2: Kd = 200 nM; GLP: Kd = 306 nM). It effectively reduces the protein levels of BRD4 short isoforms. By directly binding to its substrate GLP, MS479 recruits the E3 ligase SPOP as a bridging protein. Additionally, MS479 can be utilized to inhibit the proliferation of colorectal cancer cells.</p>Cor e Forma:Odour SolidSJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74SP-96
CAS:<p>SP-96: Aurora B inhibitor, IC50=0.316 nM, selectively hinders MDA-MD-468 growth, GI50=107 nM, for triple-negative breast cancer research.</p>Fórmula:C25H20FN7OPureza:99.54%Cor e Forma:SolidPeso molecular:453.47Cath-L-dBET1
<p>Cath-L-dBET1 is a PROTAC degrader targeting BRD4. It has an IC50 value of 2.8 μM in MDA-MB-231 cells. Activated by cathepsin L (Cath-L), Cath-L-dBET1 recruits E3 ubiquitin ligase to degrade BRD4 via the ubiquitin-proteasome system. Hyp-dBET1 is applicable for antitumor research.</p>Cor e Forma:Odour SolidTCIP3
CAS:<p>TCIP3 is a bivalent molecular glue (molecular glue) that can simultaneously bind to both p300/CBP and BCL6. It redirects p300 and CBP to activate programmed cell death genes, which are typically repressed by the oncogenic driver BCL6. TCIP3 is useful for studying diffuse large B-cell lymphoma (DLBCL) and is not toxic to untransformed tonsil lymphocytes or fibroblasts.</p>Fórmula:C58H71ClF2N16O7Cor e Forma:SolidPeso molecular:1177.74SIRT1-IN-1
CAS:<p>SIRT1-IN-1 is a selective inhibitor of SIRT1 with an IC50 of 205 nM.Cost-effective and quality-assured.</p>Fórmula:C14H16N2OPureza:99.58%Cor e Forma:SolidPeso molecular:228.29pan-BET/BD2-IN-1
<p>Pan-BET/BD2-IN-1 (compound 6b) is a selective BET protein inhibitor with BRDT-1Ki of 1.05 μM and BRD4-1Ki of 0.68 μM. It effectively inhibits the growth of MM.1S cancer cells with an IC50 value of 2.6 μM.</p>Cor e Forma:Odour SolidMenin-KMT2A-IN-1
<p>Menin–KMT2A-IN-1 (Compound 20) is an inhibitor of menin–KMT2A, binding to menin with an IC50 of 8 nM, and disrupting the interaction between menin and lysine methyltransferase 2A (KMT2A). It inhibits hERG channels with an IC50 of 65 μM and suppresses MV4-11 cells with an IC50 of 74 nM. Furthermore, Menin–KMT2A-IN-1 exhibits favorable pharmacokinetic properties in CD-1 mice, with an oral bioavailability of 74%.</p>Fórmula:C28H35FN6O3Cor e Forma:SolidPeso molecular:522.61VinSpinIn
CAS:<p>VinSpinIn is a probe for the Spin family proteins.</p>Fórmula:C42H58N8O4Cor e Forma:SolidPeso molecular:738.98SIRT5 inhibitor 9
CAS:<p>SIRT5 inhibitor 9 (compound 14) is a moderately selective and substrate-competitive SIRT5 inhibitor with IC50=4.07 μM and has potential anticancer effects.</p>Fórmula:C24H29ClN8O4SPureza:98.68%Cor e Forma:SolidPeso molecular:561.06(rel)-Tranylcypromine D5 hydrochloride
CAS:<p>(rel)-Tranylcypromine D5 hydrochloride is a deuterium labeled (rel)-Tranylcypromine hydrochloride.</p>Fórmula:C9H12ClNPureza:98%Cor e Forma:SolidPeso molecular:174.682PRMT3-IN-4
<p>PRMT3-IN-4 (intermediate 15) is an inhibitor of Protein arginine methyltransferase 3 (PRMT3) and serves as the active control for SGC707. It can be utilized in the synthesis of PROTACs targeting PRMT3 and is applicable in research related to leukemia.</p>Cor e Forma:Odour SolidSIRT5 inhibitor 8
CAS:<p>SIRT5 inhibitor 8 (compound 10) is a moderately selective and substrate-competitive SIRT5 inhibitor with IC50=5.38 μM, with potential anticancer effects.</p>Fórmula:C22H25ClN8O2SPureza:99.56%Cor e Forma:SolidPeso molecular:501HDAC8-IN-10
<p>HDAC8-IN-10 (compound 15) serves as a potent inhibitor of HDAC8, exhibiting an IC50 value of 7.6 nM. It also acts as a ligand for the HDAC8 target protein, utilized in the synthesis of PROTAC YX862.</p>Cor e Forma:Odour SolidSMD-3236
CAS:<p>SMD-3236 is a PRAOTAC degrader targeting SMARCA2, designed using SMARCA ligand and VHL-1 ligand, and exhibits prolonged anti-tumor activity in vivo. SMARCA2 acts as a synthetic lethal target in cancer cells lacking SMARCA4, with SMD-3236 showing 2000-fold selectivity for SMARCA2 over SMARCA4, having a DC50 of less than 1 nM and a Dmax of over 95%. In the human cancer xenograft models deficient in SMARCA4, notably the H838 model, SMD-3236 effectively induces loss of SMARCA2 in tumor tissue while sparing the SMARCA4 protein, thereby inhibiting tumor growth. The compound consists of a target protein ligand (red part) SMI-1074, a PROTAC linker (black part) (trans-4-Ethynylcyclohexyl)methyl methanesulfonate, and an E3 ligase ligand (blue part) SMARCA2 ligand-14, forming the E3LigaseLigand-linker Conjugate 159.</p>Fórmula:C61H75ClN10O5SCor e Forma:SolidPeso molecular:1095.83OARV-771
CAS:<p>OARV-771: VHL-based PROTAC targeting BET; DC50: Brd4-6nM, Brd2-1nM, Brd3-4nM; enhanced cell permeability.</p>Fórmula:C49H59ClN8O8S2Cor e Forma:SolidPeso molecular:987.62PROTAC BRD4-binding moiety 1
CAS:<p>BRD4-binding moiety 1 links to cereblon, forming a PROTAC that degrades BRD4 efficiently.</p>Fórmula:C23H21N3O2Pureza:98%Cor e Forma:SolidPeso molecular:371.43Mz325
<p>Mz325 serves as a dual inhibitor of both HDAC and Sirt2, exhibiting an IC50 of 9.7 µM against Sirt2, which are implicated in the pathogenesis of cancer and</p>Pureza:98%Cor e Forma:Odour SolidHDAC1-IN-9
<p>HDAC1-IN-9 (13c) is an HDAC1 inhibitor. It inhibits the HDAC1 enzyme with an IC50 value of 1.07 µM. This compound exhibits the strongest antiproliferative activity against HT-29 (human colon adenocarcinoma cells), with an IC50 of 1.78 μM. In HCT-116 (human colon cancer cells), HDAC1-IN-9 significantly induces apoptosis. Additionally, HDAC1-IN-9 possesses antiangiogenic properties, reducing the expression levels of VEGFR-2 and phosphorylated VEGFR-2 (pVEGFR-2) by approximately 80%.</p>Fórmula:C17H17N3O3Cor e Forma:SolidPeso molecular:311.34PROTAC BRD4 Degrader-10
CAS:<p>Compound 8b, a dual-ligand PROTAC, targets VHL & BRD4, degrades BRD4 in PC3 cells; conjugates with STEAP1/CLL1, DC50: 1.3/18 nM.</p>Fórmula:C59H71F2N9O15S4Cor e Forma:SolidPeso molecular:1312.5Pim-1 kinase inhibitor 11
<p>Pim-1 kinase inhibitor 11 (10f) is an inhibitor of PIM-1 with an IC50 value of 0.18 μM. It exhibits anticancer activity by inducing apoptosis and causing cell cycle arrest.</p>Cor e Forma:Odour SolidUzansertib
CAS:<p>Uzansertib (INCB053914) is a potent pan-PIM kinase inhibitor with low IC50s: 0.24, 30, 0.12 nM for PIM1, 2, 3; hinders hematologic tumor growth.</p>Fórmula:C26H26F3N5O3Cor e Forma:SolidPeso molecular:513.51Izilendustat
CAS:<p>Tert-butyl compound inhibits human EGLN-1; confirmed by spectrometry after 20 mins.</p>Fórmula:C22H28ClN3O4Pureza:99.95%Cor e Forma:SolidPeso molecular:433.93α-Hydroxyglutaric Acid
CAS:<p>α-Hydroxyglutaric Acid is a natural product for research related to life sciences. The catalog number is T36624 and the CAS number is 2889-31-8.</p>Fórmula:C5H8O5Cor e Forma:SolidPeso molecular:148.1142-Methylquinazolin-4-ol
CAS:<p>Compound 1769-24-0 is a natural product for research related to life sciences. The catalog number is TPL0186 and the CAS number is 1769-24-0.</p>Fórmula:C9H8N2OPureza:99.98%Cor e Forma:SolidPeso molecular:160.17R 8605
CAS:<p>R 8605 is a third-generation retinoid.</p>Fórmula:C22H27NO4Cor e Forma:SolidPeso molecular:369.45PROTAC BRM degrader-1
CAS:<p>PROTAC BRM degrader-1 (compound 17) serves as a PROTAC-based degrader targeting both BRM and BRG1, exhibiting DC50 values of 93 pM and 4.9 nM, respectively [1].</p>Fórmula:C57H69N11O8SCor e Forma:SolidPeso molecular:1068.29TB22
<p>TB22 is a non-nucleoside inhibitor of DOT1LR231Q with anticancer activity. It inhibits the malignant phenotype of lung cancer cells harboring the R231Q mutation via the MAPK/ERK signaling pathway, making it useful for lung cancer research.</p>Cor e Forma:Odour SolidUNC10142
<p>UNC10142 (Compound 44) is a small-molecule antagonist of CHD1, with a binding IC50 value of 1.7 μM. It induces a dose-dependent reduction in the viability of PTEN-deficient prostate cancer cells.</p>Fórmula:C33H52N6O3Cor e Forma:SolidPeso molecular:580.8SW2_152F
<p>SW2_152F: Potent CBX2 ChD inhibitor, Kd 80 nM, 24-1000x selective over other CBXs in vitro.</p>Fórmula:C45H62Cl3N7O8Cor e Forma:SolidPeso molecular:935.37BTR2004
<p>BTR2004 is a selective PROTAC degrader targeting the BET family (BRD2/3/4) proteins. It facilitates the formation of a ternary complex with BRD proteins and KLHL20, leading to ubiquitination and proteasomal degradation via the UPS pathway. BTR2004 shows potential for research in PC3 prostate cancer and MDA-MB-231 breast cancer cell lines.</p>Cor e Forma:Odour SolidNF-κB/HIF-1α-IN-1
<p>NF-κB/HIF-1α-IN-1 (compound 9c) effectively inhibits the NF-κB activation pathway and demonstrates selective antifibrotic activity. This compound exhibits no significant cytotoxicity in NCI tumor cell lines. In rat models, NF-κB/HIF-1α-IN-1 successfully ameliorates liver fibrosis, suppresses the expression levels of NF-κB and HIF-1α, and induces Nrf2.</p>Fórmula:C24H27N7O4Cor e Forma:SolidPeso molecular:477.21245Biguanide
CAS:<p>Biguanide can reduce oxidative stress in rats with hyperglycemia.</p>Fórmula:C2H7N5Cor e Forma:SolidPeso molecular:101.11BETd-246
CAS:<p>BETd-246 is an inhibitor of second-generation and PROTAC-based BET bromodomain (BRD), show antitumor activity.</p>Fórmula:C48H55N11O10Pureza:98%Cor e Forma:SolidPeso molecular:946.02SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SCor e Forma:SolidPeso molecular:873.94HSP90/LSD1-IN-1
<p>HSP90/LSD1-IN-1 (compound 6) is a dual inhibitor of HSP90 and LSD1. This compound effectively inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI50 values of 0.24 μM and 0.30 μM, respectively.</p>Cor e Forma:Odour Solid
![5H-BENZO[E]PYRIDO[3,2-B][1,4]DIAZEPIN-6(11H)-ONE](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTD1133.webp&w=3840&q=75)
![[Ala107]MBP(104-118)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1887.webp&w=3840&q=75)
